DiaSorin Launches Simplexa VZV Direct Molecular Assay in the European Market

October 12th, 2018 - Saluggia (VC) - DiaSorin (FTSE Mid Cap: DIA) announced to have received CE marking for its new Simplexa VZV Direct assay.

The new molecular diagnostic test enables the direct detection of varicella-zoster virus (VZV) DNA from cerebrospinal fluid (CSF). The assay was designed for use on the LIAISON MDX instrument and will be able to run alongside DiaSorin Molecular’s Simplexa HSV 1 & 2 Direct assay, generating comprehensive and actionable insight for patients with suspected infections of the central nervous system (CNS).

VZV causes varicella (chickenpox), a highly communicable disease that is usually contracted in early childhood. Chickenpox is usually a mild disease, but can cause complications and, in rare instances, death. After initial infection, VZV becomes latent in sensory nerve ganglia. Reactivation occurs with increased age or immunosuppression and causes herpes zoster (shingles), a painful condition associated with complications including post-herpetic neuralgia and CNS infections.

Although several vaccines have been available since the 1990s, recommendations and implementation vary by country. It is estimated that greater than 90% of the population will acquire the disease by the age of 15 and each of these persons is at risk for developing encephalitis caused by VZV.

“Our VZV assay delivers answers in about an hour, features an easy workflow with minimal hands-on time and does not require upfront extraction.” said Michelle Tabb, Chief Scientific Officer at DiaSorin Molecular LLC. “The assay is fast, giving the physician the targeted answers he/she is looking for in a timely manner.”

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasonr.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasonr.it